Hepatitis B future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Currently, new forms of treatment, such as the combination therapy with [[interferon-α]] and [[lamivudine]] for patients who failed [[interferon-α]] monotherapy is under investigation.<ref name=WHO1>{{cite web | title = Hepatitis B | url = http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index3.html }}</ref> | Currently, new forms of treatment, such as the combination therapy with [[interferon-α]] and [[lamivudine]] for patients who failed [[interferon-α]] monotherapy is under investigation.<ref name=WHO1>{{cite web | title = Hepatitis B | url = http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index3.html }}</ref> | ||
Future studies and monitoring are required to evaluate the genotypic resistance to nucleoside and nucleotide therapy. | |||
==References== | ==References== | ||
Revision as of 22:12, 2 August 2014
|
Hepatitis B |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatitis B future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hepatitis B future or investigational therapies |
|
Risk calculators and risk factors for Hepatitis B future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Currently, new forms of treatment, such as the combination therapy with interferon-α and lamivudine for patients who failed interferon-α monotherapy is under investigation.[1]
Future studies and monitoring are required to evaluate the genotypic resistance to nucleoside and nucleotide therapy.